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Abstract
Background: Human African trypanosomiasis (HAT) is an important public health problem in sub-Saharan Africa, affecting
hundreds of thousands of individuals. An urgent need exists for the discovery and development of new, safe, and effective
drugs to treat HAT, as existing therapies suffer from poor safety profiles, difficult treatment regimens, limited effectiveness,
and a high cost of goods. We have discovered and optimized a novel class of small-molecule boron-containing compounds,
benzoxaboroles, to identify SCYX-7158 as an effective, safe and orally active treatment for HAT.
Methodology/Principal Findings: A drug discovery project employing integrated biological screening, medicinal chemistry
and pharmacokinetic characterization identified SCYX-7158 as an optimized analog, as it is active in vitro against relevant
strains of Trypanosoma brucei, including T. b. rhodesiense and T. b. gambiense, is efficacious in both stage 1 and stage 2
murine HAT models and has physicochemical and in vitro absorption, distribution, metabolism, elimination and toxicology
(ADMET) properties consistent with the compound being orally available, metabolically stable and CNS permeable. In a
murine stage 2 study, SCYX-7158 is effective orally at doses as low as 12.5 mg/kg (QD67 days). In vivo pharmacokinetic
characterization of SCYX-7158 demonstrates that the compound is highly bioavailable in rodents and non-human primates,
has low intravenous plasma clearance and has a 24-h elimination half-life and a volume of distribution that indicate good
tissue distribution. Most importantly, in rodents brain exposure of SCYX-7158 is high, with Cmax .10 mg/mL and AUC0–24 hr
.100 mg*h/mL following a 25 mg/kg oral dose. Furthermore, SCYX-7158 readily distributes into cerebrospinal fluid to
achieve therapeutically relevant concentrations in this compartment.
Conclusions/Significance: The biological and pharmacokinetic properties of SCYX-7158 suggest that this compound will be
efficacious and safe to treat stage 2 HAT. SCYX-7158 has been selected to enter preclinical studies, with expected
progression to phase 1 clinical trials in 2011.
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Introduction
Human African trypanosomiasis (HAT), commonly known as
sleeping sickness, is a neglected disease caused by the kinetoplastid
parasite Trypanosoma brucei and is fatal if left untreated.[1,2] The
parasite is transmitted through the bite of the tsetse fly, and is
endemic in sub-Saharan Africa, where it is estimated that 50,000
people become infected every year.[3,4,5] The disease progresses
through two distinct stages, an initial acute stage (stage 1) where
the parasitic infection is restricted to the hemolymphatic system,
and a second stage (stage 2) where the parasites have migrated
across the blood-brain barrier and are resident in brain tissue.[6]
This latter CNS stage is particularly difficult to treat, as the two
drugs available for this purpose, melarsoprol and eflornithine, are
toxic, have limited ability to cross the blood-brain barrier, and
their activity is dependent upon complex parenteral administra-
tion procedures.[7,8] Treatment failures are therefore quite
common with these drugs. There are currently no orally active
treatments for HAT. A quite interesting recent advance in clinical
treatment of HAT has been the development of a treatment
regime which employs nifurtimox and eflornithine in combina-
tion.[9,10,11,12,13] This combination still suffers from some of
the drawbacks associated with the individual components (e.g.
parenteral administration, toxicity, cost), but significantly reduces
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Research efforts to discover new treatments for HAT have
increased over the past several years, and have begun to deliver
new biochemical targets and lead compounds.[14,15]
We have previously reported that screening of a library of
benzoxaboroles from Anacor Pharmaceuticals (CA, USA) in a
whole cell T. brucei viability assay revealed that these compounds
are effective inhibitors of parasite growth at concentrations as low
as 0.02 mg/mL.[16] From this initial screening effort, benzox-
aborole 6-carboxamides were identified as attractive leads, as they
exhibited good in vitro potency, activity in stage 1 mouse models of
HAT and promising in vitro and in vivo pharmacokinetic
properties.[17] This program yielded SCYX-6759 (see Figure 1
for chemical structures) - the first compound with sufficient
potency, pharmacokinetic properties and blood-brain barrier
permeability to provide complete cures in a stage 2 murine model
of HAT. While SCYX-6759 was fully efficacious in the stage 2
mouse model following twice-daily intraperitoneal administration
at a dose of 50 mg/kg (100 mg/kg/day) for 14 days, it exhibited
only partial efficacy in the same model following twice-daily oral
administration at 50 mg/kg for 7 days, and was not active at lower
doses or when administered in a once-daily paradigm. This
pharmacodynamic relationship was consistent with the in vivo
pharmacokinetics of SCYX-6759 measured in mice, which
demonstrated that, although this compound was well absorbed
following oral administration and provided drug concentrations in
plasma well in excess of the in vitro minimum inhibitory
concentration (MIC), drug concentrations in the brain fell below
the MIC by approximately 12 h post-dose following either single
oral doses or a 7-day repeat oral dosing regimen matched to the
stage 2 efficacy model. Consequently, further optimization of the
lead series focused on improvement of the pharmacokinetic
properties of the series, with particular emphasis on improving the
extent and duration of brain exposure. Of several strategies
pursued to improve brain exposure of the benzoxaborole 6-
carboxamides, the approach which provided the best balance of
potency and pharmacokinetics involved the installation of
substituents at the C(3) position of the benzoxaborole scaffold.
In particular, the C(3)-dimethyl analog SCYX-7158 (Figure 1)
exhibited a profile supportive of progression to preclinical and
clinical studies.
Materials and Methods
Ethics statement
Animal studies were carried out in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
pharmacokinetic (PK) studies were performed by AAALAC
accredited facilities following an internal approval by their IACUC
boards. Pharmacokinetic studies in rodents, beagle dogs and
cynomolgus monkeys were performed by Vivisource Laboratories
Inc (Waltham, MA; USDA# 14-R-0185, OLAW# A4543-01),
Sinclair Research Center, LLC (Columbia, MO; USDA# 43-R-
0122, OLAW# A4333-01) or SNBL USA (Everett, WA; USDA#
91-R-0053, OLAW# A4261-01), respectively. Blood collection
from mice was performed under anesthesia; brain collection was
performed following euthanasia. Collection of serial blood samples
from rats was performed from tail vein venipuncture, or via a
venous access port.
Efficacy studies were conducted in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee of Pace University (Animal Assurance Welfare
Number: A3112-01). Surviving animals are euthanized by carbon
dioxide asphyxiation in sealed containers as approved by the
American Veterinary Association. All efforts were made to
minimize suffering; for example, in efficacy studies conducted at
Pace University, animals were checked for parasitemia once per
week and were immediately removed from cages and euthanized if
parasites were found in a tail vein blood sample.
Test compounds
SCYX-6759 [4-fluoro-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]ox-
aborol-6-yl)-2-trifluoromethylbenzamide] and SCYX-7158 [4-fluoro
-N-(1-hydroxy-3,3-dimethyl-1,3-dihydro-benzo[c][1,2]oxaborol-6-yl-
2-trifluoromethyl benzamide] were prepared as 10 mg/mL stocks in
dimethyl sulfoxide (DMSO) for in vitro biological and absorption,
distribution, metabolism and excretion (ADME) assays.
Trypanosome and cell culture
The bloodstream-form T. b. brucei 427 strain was obtained from
Dr. K. Stuart (Seattle Biomedical Research Institute, Seattle, WA)
Figure 1. Chemical structures of compounds.
doi:10.1371/journal.pntd.0001151.g001
Author Summary
Human African trypanosomiasis (HAT) is caused by
infection with the parasite Trypanosoma brucei and is an
important public health problem in sub-Saharan Africa.
New, safe, and effective drugs are urgently needed to treat
HAT, particularly stage 2 disease where the parasite infects
the brain. Existing therapies for HAT have poor safety
profiles, difficult treatment regimens, limited effectiveness,
and a high cost of goods. Through an integrated drug
discovery project, we have discovered and optimized a
novel class of boron-containing small molecules, benzox-
aboroles, to deliver SCYX-7158, an orally active preclinical
drug candidate. SCYX-7158 cured mice infected with T.
brucei, both in the blood and in the brain. Extensive
pharmacokinetic characterization of SCYX-7158 in rodents
and non-human primates supports the potential of this
drug candidate for progression to IND-enabling studies in
advance of clinical trials for stage 2 HAT.
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vitro. Additional strains used in vitro include T. b. rhodesiense
STIB900, isolated in 1992 from a patient in Tanzania, and T. b.
gambiense 108R, isolated from a patient in Democratic Republic of
Congo in 2005. T. b. brucei EATRO 110 was a generous gift from
the late William Trager of the Rockefeller University. T. b. brucei
TREU 667 strains were kindly provided by F. W. Jennings at the
University of Glasgow. Both T. b. brucei EATRO 110 and TREU
667 were cultured according to previously described conditions
and used for in vivo studies.[18,19]
T. b. brucei was cultured in complete HMI-9 medium,[20] which
contains 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA),
10% Serum Plus medium (SAFC Biosciences, Lenexa, KS), and
100 units/mL penicillin and 0.1 mg/mL streptomycin. The
trypanosomes were propagated in T-25 vented cap flasks (Corning
Inc., Lowell, MA) at 37uC and 5% CO2 with humidity. To ensure
log growth phase, trypanosomes were sub-cultured at appropriate
dilutions (typically 1:100) every 2–3 days in fresh HMI-9 medium.
T. b. rhodesiense parasites were grown in MEM medium with Earle’s
salts supplemented with 15% horse serum. For T. b. gambiense, the
MEM medium was supplemented with 5% heat-inactivated fetal
calf serum (FCS) and 15% human serum.[21] L929 mouse
fibroblast cells (ATCC CCL1, American Type Culture Collection,
Rockville, MD) were used to determine parasite versus mamma-
lian cell selectivity. Cells were cultured in Dulbecco’s Modified
Eagle Medium (DMEM), supplemented with 10% FBS, L-
glutamine and 100 units/mL penicillin and 0.1 mg/mL strepto-
mycin. MDCKII-hMDR1 cells were generously provided by P.
Borst at the Netherlands Kancer Institute. Cells were cultured in
DMEM with Glutamax, 10% (v/v) FBS, and 100 units/mL
penicillin and 0.1 mg/mL streptomycin. Cell monolayers were fed
with cell culture media 24 h after seeding and used for
permeability studies 3 days later.
In vitro compound sensitivity assays
Compounds to be tested were serially diluted in DMSO and
added to 96-well plates to give final concentrations ranging from 5
to 0.01 mg/mL. T. b. brucei parasites in the log phase of growth
were diluted in HMI-9 media and added to each well for a final
concentration of 1610
4 parasites per well. For the sensitivity assays
using T. b. rhodesiense and T. b. gambiense, pararasites were cultured
in MEM supplemented with Baltz components (8), diluted in the
aforementioned culture media, and added to each well at a density
of 1610
3 cells/well. The final concentration of DMSO was 0.5%
and the total volume was 100 mL/well. After a 72 h incubation,
resazurin (Sigma-Aldrich, St. Louis, MO) was added to each well
[20 mL of 25 mg/100 mL stock in phosphate buffered saline
(PBS)] and incubated for an additional 4–6 h.[22] To assess cell
viability, fluorescence was quantified using an EnVision Multilabel
Plate Reader (Perkin Elmer, Waltham, MA) at an excitation
wavelength of 530 nm and emission of 590 nm. Triplicate data
points were averaged to generate sigmoidal dose-response curves
and determine IC50 values using XLfit curve fitting software from
IDBS (Guilford, UK). The IC50 is defined as the amount of
compound required to decrease parasite or cell viability by 50%
compared to those grown in the absence of the test compound.
The MIC, defined as the lowest concentration of compound that
completely inhibits visible parasite growth, was determined by
visual inspection of 96-well plates after 48–72 h of incubation with
the test compounds. To evaluate the effects of serum on
trypanocidal activity, assays were performed in the presence of
increasing concentration (2.5% to 50%) of fetal calf serum
(Invitrogen, Carlsbad, CA). The results were expressed as a fold-
change in IC50 values relative to standard conditions (10% FCS).
An evaluation of mammalian cell cytotoxicity was carried out in
parallel with the trypanosome sensitivity assays. L929 mouse
fibroblast cells were seeded at 2610
3 per well and handled as
described above for the trypanosome sensitivity assay.
Time-kill assays
The assessment of oxaborole-mediated killing of T. b. brucei in
vitro was conducted using the CellTiter Glo kit (Promega, Inc.,
Madison, WI) to measure trypanosome ATP content as a real-time
indicator of viability. Test compounds were serially diluted from 5
to 0.01 mg/mL into white wall-clear bottom 96-well plates
(Corning Inc., Lowell, MA) containing HMI-9 media. 1610
4
trypanosomes were added to each well. At specified intervals, the
CellTiter Glo reagent was added to lyse the parasites and the
plates were incubated for 10 min in the dark. Luminescence was
quantified using an EnVision plate reader. All determinations were
done in duplicate. Time-kill parameters were determined from
plots of parasite viability versus incubation time for each
concentration tested.
Examination of reversibility of trypanocidal effects
To establish the time and concentration required to cause
persistent or irreversible effects by oxaboroles, T. b. brucei parasites
were assessed for their ability to recover from transient exposure to
test compounds. Trypanosomes were seeded in clear 96-well V-
bottom plates at a density of 1610
5 parasites per well and
incubated with serially diluted test compound (from 10 to 0.02 mg/
mL). One plate was prepared for each time point. At the
designated time, a plate was removed from the incubator and spun
at 2,600 g for 5 min to sediment the parasites. The supernatant
was aspirated and 100 mL of warmed HMI-9 media was added to
each well. The wash was repeated twice more. The parasites were
resuspended in 100 mL of warmed media and 20 mL of this
suspension was added to 80 mL of HMI-9 media in triplicate
plates. Following a 72 h incubation, resazurin was added and
trypanocidal activity determined as described for the in vitro
sensitivity assay.
Efficacy in the mouse model for acute HAT
For efficacy studies against acute infections, groups of 3–5
female Swiss Webster mice (Ace Animals, Boyertown, PA) were
injected intraperitoneally (i.p.) with freshly drawn infected rat
blood containing 2.5610
5 trypanosomes (T. b. brucei EATRO 110
strain). The infection was allowed to progress for 24 h before
treatment. Test compound was then given daily by bolus i.p.
injection or oral gavage. Oxaborole compounds were formulated
in 2% ethanol/5% dextrose and were given at a dose volume of
200 mL (containing 1.25 to 50 mg/kg) for a 25 g animal. Animals
were monitored daily for signs of compound toxicity and clinical
signs of trypanosomiasis for a period of 30 days. Mice were
checked for parasitemia once per week by microscopic examina-
tion of smears prepared from the tail vein blood of animals.
Animals remaining parasite free for more than 30 days beyond the
end of the treatment period were considered cured. Control
untreated animals typically succumbed to the infection within 4–5
days following i.p. inoculation with parasites.
Efficacy in mouse model for chronic (CNS) HAT
For evaluation against late-stage CNS infections, a chronic
disease inducing strain (TREU 667) of T. b. brucei was used.[19]
Mice were divided into groups of ten and each animal was infected
i.p. with 1610
4 parasites (200 mL). As a positive control, a group of
mice were treated with a single 10 mg/kg dose of berenil (Sigma-
Benzoxaborole to Treat Sleeping Sickness
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after infection. Infection in the remaining groups of animals was
allowed to proceed for 21 days before treatment with either berenil
(single i.p. dose at 10 mg/kg) or test compound given i.p. or orally
twice daily for 7 or 14 days. Animals were checked for parasitemia
once per week and were immediately removed from the cages and
euthanized upon recrudescence. Animals were considered to be
cured of a CNS infection if they were aparasitemic for at least 180
days after the end of the treatment period. Additionally, brain
homogenates or blood of oxaborole-cured animals failed to
generate infection when injected into mice immunosuppressed
with cytoxan (40 mg/kg, QD x 2 d).
Plasma protein and brain tissue binding
Binding to human or mouse plasma proteins or mouse brain
homogenate was determined by rapid equilibrium dialysis (RED)
(Pierce, Rockford, IL) using a 48-well plate-based format
according to the manufacturer’s instructions. Briefly, test com-
pound at the required concentrations was added to fresh human or
mouse plasma (Bioreclamation, Liverpool, NY) or freshly prepared
mouse brain homogenate. Duplicate aliquots of each sample were
transferred into the sample chambers of the RED devices, and
dialysis buffer (BupH PBS) was added to the buffer chambers. The
plates were sealed and incubated at 37uC for 4 h. After dialysis,
samples collected from the buffer and tissue chambers were treated
with ice-cold methanol (3 volumes for plasma, 4 volumes for brain)
to precipitate proteins. The treated samples were centrifuged for
10 min at 3610
3 ga t1 5 uC. The supernatants were assayed for
test compound by LC-MS/MS. Calibration standards and quality
control samples were prepared in matched matrix and assayed
with samples. Values for unbound and bound fractions and mass
balance were calculated. Concordance of binding for each batch
of plasma was confirmed by assay of warfarin, imipramine and
carbamezapine. Acceptance criterion for mass balance was 70–
120%.
In vitro metabolism
Metabolic stability was evaluated using mixed gender CD-1
mouse or human liver microsomal fractions (XenoTech, Lenexa,
KS). Compounds (1 mM) were incubated with microsomes
(1.05 mg/mL protein) for 0, 10, 15 and 30 min at 37uCi na n
oxygen and humidity enriched environment in the presence of an
NADPH-regenerating system. Each compound was also incubat-
ed, under the same conditions, with CD-1 mouse, Sprague-
Dawley rat, beagle dog, cynomolgus monkey, and human liver S9
sub-cellular fractions (2 mg/mL protein)[23] for 0, 15, 30 and
60 min. At the end of each incubation period, the reactions were
quenched with 3 volumes of ice-cold methanol. Supernatants from
the incubation mixtures were analyzed for parent compound by
LC-MS/MS. Metabolic competencies of microsomal and S9
fractions were confirmed using control compounds 7-ethoxycou-
marin, propranolol and verapamil. Intrinsic clearance (CLint) and
half-life (tK) values were determined for each compound.
In vitro prediction of blood-brain barrier permeability and
P-glycoprotein (P-gp) mediated efflux transport
The propensity of the compound to cross the blood-brain
barrier was examined using an in vitro MDCKII-hMDR1 transwell
assay.[24] MDCKII-hMDR1 cells were seeded at density of
3610
5 cells per well onto microporous polycarbonate membranes
in 12 well Costar Transwell plates (Corning Inc., Lowell, MA).
The cells were used for permeability studies 3 days later. Trans-
epithelial resistance (TEER) was measured for each insert to
ensure the integrity of the monolayer (acceptable TEER .50
Vcm
2).
The permeability and propensity for P-gp-mediated efflux was
evaluated by adding each compound at a concentration of 3 mM,
in the presence or absence of 2 mM GF120918, to the apical
compartment. Competency of the P-gp efflux transporter was
confirmed by assay of propranolol (non-substrate) and amprenavir
(substrate). Cell monolayers were incubated in triplicate with
shaking (160 rpm) at 37uC in a 5% CO2-enriched humidified
atmosphere for 1 h. Samples were removed from the apical and
basolateral compartments after incubation and assayed for test
compound concentrations by LC-MS/MS. Values for mass
balance, PappARB, PappARB+GF918, and absorption quotient
(AQ) were calculated for each compound.[25,26,27] Acceptance
criterion for mass balance was 70–120%.
In vitro stability in mouse brain homogenate
The stability of each oxaborole in the CNS tissue was evaluated
by incubation in fresh rodent brain homogenate. SCYX-7158 was
incubated in freshly prepared homogenates of mouse brain tissue
for 5 h at 37uC with gentle shaking. After incubation, the reactions
were quenched with 4 volumes of ice-cold methanol. Supernatants
from the incubation mixtures were analyzed for parent compound
by LC-MS/MS.
In vitro inhibition of cytochrome P450 enzymes
The potential for compound to exert drug-drug interactions that
are mediated through inhibition of cytochrome P450 activities was
assessed using P450-Glo assay kits (Promega Inc., Madison, WI).
Assays for human cytochrome P450 isoforms 3A4, 1A2, 2C9,
2C19, and 2D6 were performed in triplicate according to the
manufacturer’s instructions over the concentration range 1–
100 mM (n=6 levels). Briefly, SCYX-7158 was added to
membrane preparations containing human recombinant
CYP450 enzymes together with luminogenic substrates specific
to each isoform. Specific CYP450 inhibitors were included as
positive controls (ketoconazole, CYP3A4; alpha-napthoflavone,
1A2; sulfaphenazole, CYP2C9; troglitazone, 2C19, and quinidine,
CYP2D6). Reactions were initiated by addition of NADPH-
regenerating solution and were allowed to incubate for an
additional 15–30 min (isoform dependent). Luciferin detection
reagent, containing the luciferin-labeled probe substrate, was then
added. Luminescence was recorded on an EnVision Multilabel
Plate Reader. Calculation of IC50 concentrations for each enzyme
was determined using GraphPad Prism (V5.01). The potential for
drug-drug interactions was characterized as high (IC50 ,1 mM),
moderate (1 – 10 mM), or low (IC50 .10 mM).[28]
Pharmacokinetics studies in rodents, beagle dogs and
non-human primates
The blood distribution, CNS disposition and pharmacokinetics
of SCYX-7158 were evaluated in infected or non-infected rodents
following intravenous or oral administration of compounds.
Pharmacokinetics and bioavailability of SCYX-7158 were also
evaluated in non-infected beagle dogs and cynomolgus monkeys.
In-life phases of non-infected rodent studies were performed at
Vivisource (Waltham, MA); studies in non-naı ¨ve cynomolgus
monkeys were performed by SNBL USA (Everett, WA).
Male CD-1 mice (,25 g), male Sprague-Dawley rats (,225 g),
or male cynomolgus monkeys (,3–5 kg) were administered test
article by either bolus intravenous injection (IV) or oral gavage.
Animals in the IV groups received a single 2 mg/kg IV dose.
Animals received oral doses of test articles as either single or twice
Benzoxaborole to Treat Sleeping Sickness
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administered as clear colorless solutions in either 50% (v/v) PEG
400: 20% (v/v) ethanol: 30% (v/v) carboxymethylcellulose (0.5%
w/v in sterile water for injection) or 2% (v/v) ethanol: 5% (w/v)
dextrose in sterile water for injection. Doses were administered in a
volume of 4 mL/kg, 2 mL/kg or 1 mL/kg for mice, rats and
cynomolgus monkeys, respectively. For pharmacokinetic analysis,
blood samples were collected from mice via cardiac puncture
under terminal anaesthesia. Serial blood samples were collected
from rats via a vascular access port located in the lateral saphenous
vein. Mice and rats were euthanized in a CO2 chamber before
collection of terminal blood samples or brain tissue. Blood samples
were collected into polypropylene tubes containing K2EDTA
anticoagulant and stored on ice until centrifuged for the
preparation of plasma. Plasma was stored at 270uC. Whole
brains were collected following decapitation, blotted dry, placed
into polypropylene containers and then immediately frozen at
approximately 270uC. CSF was collected from rats via cisterna
magna puncture, placed in sterile polypropylene tubes, and stored
at approximately 270uC.
Analysis of test compounds in biological samples
Samples of plasma (25 mL) and CSF (10 mL) were treated with 3
volumes of ice-cold methanol (containing 25 ng/mL of 2-chloro-4-
fluoro-N-(1-hydroxy-1,3-dihyrobenzo[c][1,2]oxaborol-6-yl)benza-
mide or 25 ng/mL d6-SCYX-7158 as an internal standard) to
precipitate proteins. Treated samples were gently mixed at room
temperature for 10 min, and then centrifuged at approximately
30006g for 15 min at 15uC. The supernatants were transferred to
96-well plates or HPLC vials for analysis by LC-MS/MS.
Pharmacokinetic parameters were calculated from composite
mean plasma or tissue data using non-compartmental (oral and
intravenous routes) and bi-exponential (intravenous route) analyses
in Microsoft Excel.
Results and Discussion
In vitro trypanocidal activity of SCYX-7158
In wholecell assays,SCYX-7158exhibited potentactivity against
representative T. b. brucei, T. b. rhodesiense and T. b. gambiense strains.
Parasite-mediated reduction of the pro-fluorescent dye resazurin
was used as indicator for trypanosome viability. As shown in
Table 1, IC50 values for SCYX-7158 were approximately 0.07 mg/
mL to 0.37 mg/mL following incubation of the parasite strains with
the compound for 72 h. In the T. b. brucei S427 strain, the MIC
value for SCYX-7158 was 0.6 mg/mL, approximately two times the
IC50 measured for this strain. In the T. b. brucei S427 assay, the
primary oxidative metabolite SCYX-3109 (vide infra) was inactive, as
it exhibited no inhibition of parasite growth at a concentration of
10 mM. In contrast to the potent activity of SCYX-7158 against
trypanosomes, no significant inhibition of cell proliferation was
observedinaninvitromammaliancell (L929mousecell line)assayat
drug concentrations up to 50 mg/mL.
We next evaluated the in vitro time-kill relationship for SCYX-
7158.[17,29,30] In these experiments, trypanosomes were exposed
to continuous drug pressure and survival of the parasites was
measured at several time points over 24 h. The results of this
experiment, which measured parasite ATP content as an indicator
of viability, are presented in Figure 2A. SCYX-7158 displayed
concentration-dependent trypanocidal activity characterized by
rapid onset, with greater than 50% reduction in viability within
8 h of exposure at a concentration (1.25 mg/mL) about 2 times the
MIC (0.6 mg/mL). At these concentrations, .99% of the parasites
were killed within 24 h of exposure to the compound.
The final aspect of activity of SCYX-7158 that was evaluated in
vitro was the irreversibility of the trypanocidal effect. In these
experiments (Figure 2B), we demonstrated that a short exposure
(10–12 h) to the compound was sufficient to produce irreversible
effects on trypanosome survival, albeit at a concentration of about
5 times the IC50. As was observed in the time-kill experiments,
increasing the concentration of compound above this threshold
value did not significantly alter the robustness or speed of its
trypanocidal activity.
In vivo trypanocidal activity of SCYX-7158
Our initial in vivo experiments were conducted in a mouse model
of acute trypanosomiasis. In this model, mice were infected with
2.5610
5 parasites of the T. b. brucei EATRO 110 strain. This strain
produces a robust infection in mice with rapid increases in
parasitemia, ultimately leading to death of untreated mice within
4–5 days following infection.[18] Starting 24 h after infection,
mice were administered an oral dose of SCYX-7158 once daily for
4 days. Mice treated with doses as low as 5 mg/kg/day
(administered as either 5 mg/kg once daily (QD) or 2.5 mg/kg
twice daily (BID)) exhibited a 100% cure rate (Table 2). Animals
were monitored weekly for parasitemia through 30 days after
infection. Those animals that remained parasite-free through the
entire course of the experiment were considered cured.[18]
As the in vitro time-kill and irreversibility assays suggested that
complete parasite clearance could be obtained within 12–24 h, we
examined whether a single high dose of SCYX-7158 could
produce a similar effect in vivo. In this experiment, a single 25 mg/
kg i.p. dose of SCYX-7158 produced 100% cure by the criteria
described above. Lower doses by the i.p. route, or oral
Table 1. In vitro activity of SCYX-7158.
Parasite strain IC50 (mg/mL) Comments
T. b. brucei 427 0.29260.019 (n=9) ..
T. b. rhodesiense STIB 900 0.294 (n=1) Isolated from a patient in Tanzania in 1982, adapted to cell culture at Swiss Tropical Institute.
T. b. gambiense 108R 0.165 (n=1) Isolated from a patient in DRC in 2005, relapse 8 mo. after melarsoprol treatment.
T. b. gambiense 40R 0.363 (n=1) Isolated from a patient in DRC in 2005, relapse 6 mo. after melarsoprol treatment.
T. b. gambiense ITMAP 141267 0.092 (n=1) Isolated from a patient in DRC in 1960.
T. b. gambiense Drani 0.129 (n=1) Isolated from a patient in Uganda in 1995.
T. b. gambiense DAL 1402 0.065 (n=1) Isolated from a patient in Cote d’Ivoire in 1990
Mouse L929 fibroblast . 50 (n=4) ..
doi:10.1371/journal.pntd.0001151.t001
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efficacious, increased the survival time of mice compared to
untreated controls (Table 2).
The most important need for a clinically relevant HAT drug is
the ability to cross the blood-brain barrier and kill parasites in the
brain of the patient. In order to assess the potential of SCYX-7158
to address this need, a model of the stage 2 CNS HAT was
employed.[31] In this model, mice are infected with 1610
4
parasites of the T. b. brucei TREU 667 strain, which produces a
persistent hemolymphatic infection where parasites migrate across
the blood-brain barrier within 21 days after infection.[19] Two
control groups were included in each study – a positive control
group in which animals were treated with berenil at day 4 after
infection, and a negative control group in which animals were
treated with berenil at day 21 after infection. Berenil does not cross
the blood-brain barrier, so although it is very effective in clearing
parasites from the hemolymphatic system, it is unable to clear
parasites from the CNS. Consequently, animals treated on day 4
are cured as parasites have not yet crossed the blood-brain barrier;
however, animals receiving berenil 21 days after infection do not
sustain cures and recrudesce because parasites that have infected
the CNS are able to migrate back across the blood-brain barrier
and re-infect the hemolymphatic system generally around days
35–42 after infection.[32]
We examined SCYX-7158 at several doses in this model of
Stage 2 HAT. When administered as a once daily oral dose of
12.5 mg/kg over 7 days starting on day 21 after infection, SCYX-
7158 produced an 80% cure rate of the T. b. brucei infection, with a
100% cure rate observed following 7 daily oral doses of 25 mg/kg
(Figure 3). In this model, cure is defined as lack of parasitemia in
the blood for 180 days after the last dose, together with a lack of
infection measured throughout 30 days in fresh animals inoculated
with the blood and/or brain homogenates collected from the
SCYX-7158 treated animals.
In vitro ADMET characterization of SCYX-7158
Concurrent with our studies to explore the biological activity of
SCYX-7158, we conducted extensive in vitro ADMET experiments
to help understand the ability of this compound to be effective in
the treatment of stage 2 HAT (Table 3). SCYX-7158 was
metabolically stable when incubated with liver sub-cellular
fractions from rodents, beagle dog, cynomolgus monkey and
Figure 2. In vitro trypanocidal activity of SCYX-7158. a, Parasite viability, as indicated by ATP content, following continuous exposure of T. b.
brucei 427 to SCYX-7158 at the indicated concentrations and times. Data are mean 6 s.d. b, Irreversibility of trypanocidal effect. T. b. brucei 427 were
exposed to the indicated concentrations of SCYX-7158 for the time indicated, then were sedimented by centrifugation and resuspended in drug-free
media. Parasite viability was measured at 72 h by the resazurin method as described in the Methods section.
doi:10.1371/journal.pntd.0001151.g002
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were less than 5 mL/min/mg protein and longer than 350 min
following incubation with microsomes and S9 fractions, respec-
tively. When incubated with primary hepatocytes from rat or dog
for extended periods (6–12 h), we observed the formation of two
minor metabolites. Phase 1 oxidative deboronation of SCYX-7158
yielded the diol SCYX-3109 (Figure 1) as the primary metabolite;
although less than 5% of the SCYX-7158 was metabolized over
12 h. Subsequent glucuronidation of SCYX-3109 was observed to
a small degree. In vitro SCYX-7158 showed low clearance
predictive of good exposure during in life studies.
The potential for SCYX-7158 to inhibit cytochrome P450
enzymes was evaluated using P450-Glo assays (Promega) for the
human isoforms 3A4, 1A2, 2C19, 2C9 and 2D6. The IC50 values
for SCYX-7158 in these assays were all above 10 mM, suggesting
that this compound has low risk for CYP450-based drug-drug
interactions.[28] We also evaluated the primary oxidative
metabolite, SCYX-3109, in the CYP inhibition assays, where it
exhibited IC50 values above 100 mM for the human isoforms 1A2,
2C19, 2C9 and 2D6. An IC50 of 7.5 mM for inhibition of human
CYP 3A4 was measured.
The mechanism by which SCYX-7158 is trypanocidal is
currently unknown. In order to assess potential biochemical
targets (or target classes) that might be implicated in the
mechanism of action of SCYX-7158, and to concurrently identify
any potential off-target activities of SCYX-7158 that may hold
potential for toxicity to the mammalian host, we evaluated SCYX-
7158 in an array of in vitro receptor binding and enzyme inhibition
assays. At a test concentration of 10 mM, SCYX-7158 did not
exhibit any significant binding to, or inhibition of, any of the .100
biochemical targets tested. While these results did not identify the
potential biochemical targets, we were encouraged because they
predict a low risk of mechanism-based toxicity in our animal safety
studies, which is also supported by the observation that SCYX-
Table 2. Activity of SCYX-7158 in T. b. brucei acute mouse infections.
Dose (mg/kg) Dose Frequency Duration (days) Route Cured/Total Avg. Days Parasite-Free % Cured
10 BID 4 PO 5/5 .30 100%
10 QD 4 PO 5/5 .30 100%
5 BID 4 PO 5/5 .30 100%
5 QD 4 PO 5/5 .30 100%
2.5 BID 4 PO 5/5 .30 100%
2.5 QD 4 PO 0/5 8.4 0
1.25 BID 4 PO 0/5 8 0
1.25 QD 4 PO 0/5 4.4 0
25 QD 1 IP 3/3 .30 100%
10 QD 1 IP 0/3 9.3 0
5 QD 1 IP 0/3 6 0
25 QD 1 PO 1/3 8.3 33%
doi:10.1371/journal.pntd.0001151.t002
Figure 3. SCYX-7158 cures stage 2 trypanosomiasis in mice. Kaplan-Meier parasitemia plot for female Swiss-Webster mice (n=10 per group)
after infection with T. b. brucei TREU 667 (inoculum 1610
4 parasites). Oral treatment with SCYX-7158 started on day 21 after infection at the indicated
doses (once daily for 7 days). Berenil (diminazene) was administered as a single 10 mg/kg dose intraperitoneally on either day 4 (positive control) or
day 21 (negative control). Parasitemia was assessed weekly starting on day 21 by microscopic examination of a blood sample. Animals in which
parasites were detected in the blood were sacrificed.
doi:10.1371/journal.pntd.0001151.g003
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(e.g. 200 mg/kg/day, 8 times the effective dose) which represents
the highest dose administered during efficacy studies. This dose
was based on practical considerations (e.g. solubility of compound
in vehicle and dosing volume limitations). By way of comparison,
in the closely related GVR35 stage 2 HAT model, melarsoprol
must be dosed at 10–15 mg/kg QD 65 days to effect cure, but is
toxic to mice at 20 mg/kg QD x 5 days (R. Brun, personal
communication). Preliminary toxicological evaluation of SCYX-
7158 in rats and dogs is ongoing, and will be reported as part of a
regulatory filing prior to initiation of clinical trials.
Due to implication of the hERG channel in potential
cardiovascular toxicity, specifically long QT syndrome,[33] we
evaluated SCYX-7158 in several hERG potassium channel assays.
SCYX-7158 did not exhibit any significant binding to this channel
in a radioligand binding assay (26% at 10 mM), and we confirmed
this result by investigation of the ability of SCYX-7158 to block
the hERG channel expressed in HEK-293 cells using a whole-cell
patch clamp technique.[34,35] At test concentrations of 30 and
100 mM, SCYX-7158 produced a mean fractional block of
0.10860.037 and 0.19860.018, respectively, indicative of a
hERG IC50 .100 mM.
The final in vitro toxicology study performed on SCYX-7158
was a bacterial reverse mutation (Ames) assay. In this assay, the
potential for mutagenicity of SCYX-7158 was evaluated by
exposure of several test strains of Salmonella typhimurium and
Escherichia coli, both in the presence and absence of rat liver S9
fraction.[36] At a maximum dose of 5000 mg per plate, no positive
mutagenic response was observed in any of the test strains
employed, leading to the conclusion that SCYX-7158 is classified
as an Ames-negative compound.
Binding of SCYX-7158 to human and mouse plasma proteins
was determined by rapid equilibrium dialysis (RED, Pierce).
Binding to plasma proteins was concentration dependent where
the unbound fraction (fu) of SCYX-7158 in mouse plasma at the
MIC (,0.6 mg/mL) was 0.3% rising to 3.2% at plasma
concentrations equivalent to Cmax at steady-state (,15 mg/mL,
25 mg/kg doses). Protein binding was modestly weaker in human
plasma where unbound fraction was 1.3% and 5.5% with 1 mg/
mL and 50 mg/mL SCYX-7158; the corresponding values for
mouse plasma were 0.32% and 4.63%, respectively. Binding to
mouse brain tissue was independent of concentration (fubrain
,5%). In these experiments, SCYX-7158 was also stable when
incubated with plasma or brain homogenate for 4 h at 37uC.
To assess the possible impact of protein binding on potency,
mouse or bovine serum was added to the in vitro T. b. brucei
inhibition assay. The resulting in vitro IC50 was attenuated by less
than 3–4 fold in the presence of 25% mouse serum or 50% bovine
serum. These results suggest low affinity for protein binding (data
not shown). In contrast, the in vitro potency of suramin, the current
standard of care for stage 1 HAT (hemolymphatic stage), when
tested under the same conditions, was attenuated by greater than
25 fold.
Successful treatment of stage 2 HAT requires therapeutically
relevant exposure in the CNS compartment. To achieve this,
SCYX-7158 needed to readily cross the blood-brain barrier and
not be a substrate for the P-glycoprotein (P-gp) efflux transporter.
An early prediction of the ability of SCYX-7158 to cross the
blood-brain barrier was obtained by the assessment of the
permeability in the MDCKII-hMDR1 monolayer transport
assay.[24] In this assay, MDCKII cells over-expressing P-gp were
grown to confluence on transwell membranes and incubated with
SCYX-7158 (1.1 mg/mL). Apparent permeability in the apical to
basolateral direction (PappARB) was 776 nm/s, consistent with
high blood-brain barrier permeability, where PappARB values
.150 nm/s are considered indicative of CNS exposure.[37]
Furthermore, PappARB values .50 nm/s predict rapid and
complete absorption following oral administration.[26] When the
permeability assay was performed in the presence of the known P-
gp inhibitor GF120918, the PappARB+918 value was similar at
853 nm/s. The absorption quotient (AQ), calculated from these
two values (as described in the Methods section) was 0.09,
indicating that SCYX-7158 is not a P-gp substrate.[25] Overall,
the high PappARB value and low AQ value predict that SCYX-
7158 should readily cross the blood-brain barrier and, in light of
good plasma pharmacokinetics, achieve therapeutically relevant
exposures in brain tissue following oral dosing.
In vivo pharmacokinetics of SCYX-7158
Given the attractive in vitro ADME profile of SCYX-7158, we
were confident that the compound would exhibit good in vivo
pharmacokinetics. This expectation was confirmed in mice, rats,
and monkeys following both intravenous and oral administration
(Figure 4).
In uninfected mice, 4.3 mg/kg intravenous dose of SCYX-7158
showed an apparent elimination half-life (t1/2) of 26.6 h; systemic
clearance (CL) of 0.089 L/h/kg; a volume of distribution (Vdss)o f
1.69 L/kg and area under the concentration-time curve (AUC0–24 h)
of 48 hNmg/mL. Following an oral dose of 13.4 mg/kg, which
corresponds to the lowest efficacious dose in the murine stage 2 HAT
model, SCYX-7158 was rapidly absorbed, as a Cmax of 6.96 mg/mL
was achieved in plasma at 6 h after dose, with an oral clearance (Cl/
F) value of 0.163 L/h/kg, anAUC0–24 hof 82 hNmg/mLandabsolute
oral bioavailability of 55%. After a 26 mg/kg oral dose, which
corresponds to the dosegiving a 100% cure rate in the murine stage 2
HAT model, Cmax increased to 9.8 mg/mL and the AUC0–24 h was
113 hNmg/mL.
CNS exposure was determined in homogenates prepared from
whole brain tissues. SCYX-7158 exhibited good permeability
across the blood-brain barrier and achieved measurable levels
after both intravenous and oral doses. Following intravenous
administration at 4.3 mg/kg, SCYX-7158 demonstrated a brain
AUC0–24 h of 5.57 hNmg/mL. In the study where the compound
was dosed orally at 13.4 mg/kg or 26 mg/kg, the values for Cmax
in brain tissue were 4.62 mg/mL and 8.1 mg/mL, respectively.
The corresponding values for AUC0–24 h were 31.4 hNmg/mL and
68 hNmg/mL. At these therapeutic doses, the brain to plasma ratios
of SCYX-7158 were 38% and 60% based on AUC0–24 h following
Table 3. In vitro physicochemical and ADME properties of
SCYX-7158.
Assay Key Property Value
Lipophilicity logD 3.51
Aqueous Solubility Solubility in pH 7.4 PBS 25 mM
Permeability – MDCK-MDR1 monolayer Papp ARB 776 nm/sec
Permeability – MDCK-MDR1 monolayer Papp ARB + GF120918 853 nm/sec
Permeability – MDCK-MDR1 monolayer AQ 0.09
Inhibition of CYP1A2 IC50 .100 mM
Inhibition of CYP2C19 IC50 23.1 mM
Inhibition of CYP2C9 IC50 23.5 mM
Inhibition of CYP2D6 IC50 21.1 mM
Inhibition of CYP3A4 IC50 47.4 mM
doi:10.1371/journal.pntd.0001151.t003
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7158 readily enters the CNS compartment and that disposition
occurs in a dose-dependent manner.
In uninfected rats, following oral administration of SCYX-7158
at a nominal dose of 25 mg/kg (dose affording a 100% cure rate in
mice), Cmax increased approximately 2 fold more than that in mice
(Cmax =18.2 mg/mL) and AUC0–24 h, and hence oral clearance,
improved approximately 4 fold (AUC0–24 h 291 hNmg/mL and
CL/F =0.092 L/kg/h). The time to maximum concentration was
similar to that in mice (tmax =8 h).. In the same experiment, brain
and cerebrospinal fluid (CSF) pharmacokinetics parameters were
as follows: Cmax =8.5 mg/mL in the brain, 1.08 mg/mL in the
CSF and AUC0–24 h =129 hNmg/mL in the brain and 14.6 hNmg/
mL in the CSF. The brain to plasma AUC0–24 h ratio was 44%,
which is similar to that in mice.
The pharmacokinetic properties of SCYX-7158 were also
evaluated in non-human primates following administration by
intravenous and nasogastric (NG) routes. In this study, uninfected
male and female cynomolgus monkeys were treated with SCYX-
7158 at 2 mg/kg (IV) on study day 1 and 10 mg/kg (NG) on study
day 8. Following each dose, blood samples were taken at 11 time
points between 0.17 and 72 h, and CSF was collected at 2, 6, 12,
18 and 24 h in an off-set sparse sampling paradigm. As observed
in both the mouse and rat studies, SCYX-7158 exhibited excellent
plasma pharmacokinetics, with CL of 0.022 L/h/kg; Vdss of
0.656 L/kg and area under the concentration-time curve
78.8 hNmg/mL, and 94.4 for AUC0–24 h and AUC0–inf, respective-
ly, following intravenous administration. Pharmacokinetic prop-
erties were independent of gender. In the oral phase of the study,
SCYX-7158 exhibited a Cmax of 11 mg/mL at 9.5 h after dose, an
oral clearance (Cl/F) value of 0.025 L/h/kg, an AUC0–inf of
460 hNmg/mL, corresponding to absolute oral bioavailability of
89%. Concentrations of SCYX-7158 in the CSF of non-human
primates were approximately 5% of the plasma concentration at
each time point.
In this study, we also measured concentrations of the oxidative
metabolite SCYX-3109 in plasma. In the 10 mg/kg NG group,
the concentration of SCYX-3109 was approximately 1% of the
SCYX-7158 concentration at all time points (e.g. Cmax =0.14 mg/
mL and AUC0-inf =6.4 hNmg/mL). Though not measured due to
technical limitations, we can estimate that the maximum
concentration of boric acid (borate) would be no greater than
0.02 mg/mL, as it is generated on an equimolar basis to SCYX-
3109. This concentration is below the background concentration
(0.03 – 0.10 mg/g) reported for boric acid in the human
population, and well below the concentration (1.27 mg/g) reported
as a NOAEL in rats.[38,39]
We have also measured plasma concentrations of the
oxidative metabolite SCYX-3109 in separate studies in mice
and rats. In mice, following a oral dose of 56 mg/kg SCYX-
7158, the plasma concentrations SCYX-3109 were approxi-
mately 1% of the SCYX-7158 concentration at all time points,
where the Cmax for SCYX-7158 was 18 mg/mL and for SCYX-
3109 was 0.27 mg/mL. Rats were administered an oral dose of
10 mg/kg of SCYX-7158, and concentrations of SCYX-3109
were 3-5% of the SCYX-7158 concentration at each time
point. The Cmax for SCYX-7158 was 14.3 mg/mL and for
SCYX-3109 was 0.5 mg/mL. As in the non-human primate
studies, boric acid concentrations were not measured in these
studies, but the estimated maximum concentration could be
calculated as 0.05 mg/mL and 0.09 mg/mL in mice and rats,
respectively. As with the non-human primate studies, these
concentrations of boric acid are well below the NOAEL in
rats.[38,39]
Figure 4. SCYX-7158 exhibits excellent plasma exposure across species. Male CD-1 mice, Sprague-Dawley rats, cynomolgus monkeys or
male beagle dogs were administered a single oral dose of SCYX-7158 at a dose of 25 mg/kg (mouse, rat) or 10 mg/kg (monkey, dog). Blood samples
were collected and analyzed as described in the Methods section. Data points for mouse and rat represent a single animal at each time point; data
points for cynomolgus monkey and dog represent the mean of three animals at each time point. The MIC line (red hashed line) is defined as the
lowest concentration of compound that completely inhibits visible parasite growth, determined by visual inspection of 96-well test plates after 72 h
incubation.
doi:10.1371/journal.pntd.0001151.g004
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determined in T. brucei-infected mice after 7 daily oral doses of 6,
12.5, 25, 50 or 100 mg/kg. SCYX-7158 showed dose-related
increases in exposure, although exposure increased in a less than
proportional manner (Figure 5). Brain exposure was impressive in
these mice as well. For example, following a 12.5 mg/kg oral dose,
aC max of 6.54 mg/mL and an AUC0-inf of 34.2 hNmg/mL were
achieved in mouse brain tissue; at 25 mg/kg, Cmax of 11.98 mg/
mL and an AUC0-inf of 81.5 hNmg/mL were observed. Most
importantly, brain concentrations of SCYX-7158 were maintained
at or above the MIC (0.6 mg/mL) for close to 24 h following the
25 mg/kg dose, consistent with the efficacy observed in the stage 2
HAT assay. Interestingly, efficacy correlated with total brain
exposure rather than the unbound concentration. Consistent with
minimal attenuation of in vitro potency in the presence of serum,
this likely reflects weak, non-restrictive, binding of SCYX-7158
to brain tissue complemented with rapid distribution into
trypanosomes.
The pharmacokinetic properties and efficacy of SCYX-7158 in
the stage 2 murine HAT model have demonstrated that a once-
daily oral regimen is possible during clinical application. Efficacy
in the stage 2 model was dependent on maintaining brain
concentrations above the MIC for approximately 24 h or
achieving brain concentrations above 3 times the MIC for shorter
periods of time, as depicted in Figures 2B and 5. If pharmaco-
kinetic clearance scales from pre-clinical species to humans based
on body weight or hepatic blood flow are likely, clinical dose
would be approximately 2.5 mg/kg, although this must await
confirmation in clinical trials. These observations along with in vivo
pharmacodynamic relations observed in the mouse stage 2 HAT
experiments, where maintenance of drug concentration at or
above the trypanocidal MIC for 14–20 h was sufficient to
demonstrate cures in this model, suggest that SCYX-7158 could
be a once-daily oral treatment for HAT.
Concluding Remarks
The optimization of a series of benzoxaboroles discovered to
exhibit parasitical activity against T. brucei has culminated in
the identification of SCYX-7158. We have demonstrated that
this compound is potent in in vitro trypanocidal assays and has
attractive in vitro physicochemical and ADME properties. In
animal models of HAT, SCYX-7158 exhibits significant
activity following oral administration, including cure of a
CNS T. brucei infection following 7 days administration at a
dose of 25 mg/kg. The in vivo pharmacokinetic characterization
of SCYX-7158 reveals that this compound is highly bioavail-
able across species, and can cross the blood-brain barrier to
achieve therapeutically-relevant concentrations in the brain
and cerebrospinal fluid of rodents. Based on these properties,
SCYX-7158 has been selected to enter IND-enabling preclin-
ical studies, with expected progression to phase 1 clinical trials
in 2011.
Figure 5. Time vs. concentration curves for SCYX-7158 following administration to mice infected with T. b. brucei TREU667. Female
Swiss Webster mice were administered 7 daily doses of SCYX-7158 at the indicated doses. Blood (solid lines) and brain (dashed lines) samples were
collected after the last dose and analyzed as described in the Methods section. Data points represent a single mouse at each time point. The MIC line
(red hashed line) is defined as the lowest concentration of compound that completely inhibits visible parasite growth, determined by visual
inspection of 96-well test plates after 72 h incubation.
doi:10.1371/journal.pntd.0001151.g005
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